Initiating Coverage of Scribe Therapeutics: STX-1150 Targets One-Time, Long-Term LDL-C Reduction Through PCSK9 Epigenetic Silencing

Overview

Scribe Therapeutics is a clinical-stage biotechnology company developing genetic medicines for high-prevalence diseases using engineered CRISPR technology, with a current focus on atherosclerotic cardiovascular disease (ASCVD). Its lead asset, STX-1150, uses the ELXR epigenetic silencing platform to target PCSK9 and lower LDL-C; STX-1200 targeting Lp(a) and STX-1400 targeting APOC3 remain in preclinical development.

Core views

The report’s two core conclusions are: first, STX-1150 may establish a clinical profile competitive with existing PCSK9 therapies by combining long duration with the potential safety advantage of not permanently editing DNA; second, if clinical and regulatory outcomes are successful, its commercialization feasibility is more likely to derive from Medicare Part B. This view remains constrained by substantial uncertainties around Phase 1 data, durability of efficacy, reimbursement coverage, and the competitive landscape.

Analysis framework

Goldman Sachs analyzes two investment debates—clinical competitiveness and commercialization feasibility—by comparing marketed PCSK9 therapies, siRNA, and gene-editing approaches, and constructing a peak-sales sensitivity model based on probability of success, WACC, terminal growth rate, pricing, penetration, and geographic discounts.

Methodology notes

• Technology platform assessmentELXR epigenetic silencing

  Suppresses target-gene expression through markers such as DNA methylation without altering the underlying DNA sequence.

  STX-1150 uses this mechanism to silence PCSK9, theoretically avoiding the risks of permanent off-target edits while retaining the potential for reversibility through intervention.

• Risk-adjusted valuationPOS scenario analysis

  Risk-adjusts unadjusted revenue using a program probability of success and tests the sensitivity of key assumptions.

  Goldman Sachs applies a 25% probability of success to STX-1150 in both ASCVD and HeFH indications, and analyzes the valuation effects of changes in WACC, terminal growth rate, and POS.

• Commercialization assessmentPayer access pathway analysis

  Compares reimbursement and access mechanisms across commercial insurance, Medicare Part D, and Medicare Part B.

  The report argues that Medicare Part B does not rely on PBM-driven bidding, rebates, and preferred-formulary processes, and may be better suited to high-priced, one-time genetic medicines with durable benefits.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• STX-1150

  Scribe Therapeutics’ lead clinical asset; a PCSK9 epigenetic-silencing therapy developed on the ELXR platform for patients with high LDL-C and ASCVD risk.

  Strengths

  One-time treatment with potential durability of more than 10 years; does not permanently modify DNA; preclinical dose-dependent reductions in PCSK9 and LDL-C; potential to improve long-term medication adherence.

  Weaknesses

  Still in early Phase 1; human efficacy, safety, dosing convenience, and true duration of effect have not been validated.

  Comparison

  Positioned as a one-time durable therapy versus chronically administered PCSK9 products such as Repatha, Praluent, and Leqvio; versus permanent gene editing, it theoretically offers greater reversibility and fewer concerns about permanent off-target effects.

  Risks

  Clinical translation failure, erosion of methylation markers over time, effects of hepatocyte turnover on efficacy, payer restrictions, resistance to high pricing, and intense competition.

• STX-1200

  A preclinical CRISPR gene-editing program targeting LPA to reduce Lp(a).

  Strengths

  Preclinical data indicate potential for high on-target editing and reduction of apo(a).

  Weaknesses

  Has not yet entered the clinic, and its development plan is influenced by later-stage data from competing programs.

  Comparison

  Targets an area that currently lacks approved specific Lp(a)-lowering therapies, but will need to compete with later-stage candidates.

  Risks

  Preclinical program risk, competitive CVOT outcomes, and gene-editing safety and regulatory uncertainty.

• STX-1400

  A preclinical CRISPR gene-editing program targeting APOC3 for persistent and genetic hypertriglyceridemia.

  Strengths

  Designed to provide a one-time, durable treatment, with preclinical evidence of high on-target editing and APOC3/TG reduction.

  Weaknesses

  At an early stage of development and not a near-term valuation focus of the report.

  Comparison

  Potentially differentiated from ASO and siRNA therapies requiring chronic administration.

  Risks

  Clinical development, off-target editing, competing products, and commercialization uncertainty.

Key data

• Current share price$21.19Listed on the report cover page.
• STX-1150 Phase 1 trialUp to 64 participants; initial data expected in 1H27Conducted in Australia and New Zealand, assessing safety, tolerability, and LDL-C-lowering activity.
• Preclinical LDL-C reduction52% to 68%Prototype data in non-human primates, with no apparent waning of effect over up to two years of observation.
• Potential duration of effectMore than 10 yearsA company development objective and analytical assumption, not clinically validated.
• 2036 peak salesApproximately $2.2B unadjusted; approximately $552M risk-adjustedGoldman Sachs model output.
• Probability of success assumption25%Model assumption for STX-1150 in the ASCVD and HeFH indications.
• Assumed US launch price$26KModel assumption for list price per treatment at launch, with an additional assumed 35% gross-to-net adjustment.

Impact & implications

If STX-1150 reproduces potent, durable LDL-C reduction in humans while maintaining an acceptable safety profile, it could address adherence challenges in chronic-disease treatment and create differentiation as a one-time, high-value therapy in the PCSK9 market. Conversely, any Phase 1 shortfall in safety, efficacy, or durability could materially weaken its clinical positioning, payer acceptance, and long-term revenue expectations.

Risks

• STX-1150 is only in Phase 1, and its clinical safety, tolerability, and LDL-C-lowering effect remain unvalidated.
• Long-term durability is uncertain: hepatocyte turnover and endogenous removal of methylation markers could weaken efficacy.
• The PCSK9 market already includes competitors such as Repatha, Praluent, Leqvio, and oral products, creating high clinical and commercial access barriers.
• A high-priced one-time therapy may face PBM preferred-formulary, prior-authorization, step-therapy, and rebate pressure.
• Although cardiovascular outcomes trials may not be required for approval, they could be important for driving broad commercial adoption and are costly and operationally complex.
• The model is sensitive to probability of success, pricing, penetration, discount rate, and launch timing; STX-1200 and STX-1400 are not included in the current valuation model.

What to watch

• Safety, tolerability, and LDL-C reduction data from the STX-1150 Phase 1 trial in 1H27.
• Further disclosure after Phase 1 data on efficacy magnitude, duration, route of administration, and patient selection.
• Progress toward initiating Phase 1 trials for STX-1200 or STX-1400 in early 2027.
• Potential reimbursement and payer strategy under Medicare Part B, including access feasibility with CMS.
• Clinical, regulatory, and pricing developments for PCSK9, Lp(a), and APOC3 competitors.
• Whether a partner will be needed to support costly cardiovascular outcomes trials and subsequent commercialization.